INFO & CONTACTS:  +39 02 2390 1

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Participants with Metastatic Squamous NSCLC (INTerpath-013)

Phase: Phase II clinical trials

Principal Investigator: Dott.ssa Brambilla Marta

Main Facility: Oncologia Medica 1

Drug: V940

Pathologies: Lung cancer

Randomized 1:1 Phase 2 clinical study evaluating V940 (vaccine) versus placebo in patients with squamous non-small cell lung cancer (NSCLC).**

Last update: 16/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe